AstraZeneca (AZN.L) said on Tuesday a late-stage trial failed to provide evidence that its COVID-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.
Sage Therapeutics (SAGE.O) said on Tuesday its experimental depression drug showed significant improvement in symptoms compared to placebo in a late-stage study.